Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Inv. presentation
Filed Chapter 11
Monthly oper. report
|
|
BIOVEST INTERNATIONAL INC (BVTI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/25/2010 |
8-K
| Filed a monthly operating report|
Docs:
|
"Securities Purchase Agreement, (the “Securities Purchase Agreement”), among Biovest International, Inc. (the “Company”) and the investors listed on the Schedule of Buyers attached thereto (the “Buyers”)",
"Form of Debtor in Possession Secured Convertible Note issued October 19, 2010",
"Form of Series A Warrant issued October 19, 2010",
"Form of Series B Warrant issued October 19, 2010",
"Interim Order of the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17796-KRM",
"Final Order of the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17796-KRM",
"Biovest Announces $7 Million Financing Required to Exit from Reorganization and Advance Key Regulatory and Commercial Strategies for BiovaxID® Cancer Vaccine TAMPA, FL and MINNEAPOLIS, MN - October 25, 2010 - Biovest International, Inc. today announced that the Company has entered into definitive loan documents and other agreements for the issuance of $7 million of convertible debtor-in-possession term notes and common stock purchase warrants to institutional investors. ROTH Capital Partners, LLC acted as the exclusive placement agent. The closing occurred on October 19 th , 2010, subject to the Court entering a final order approving the transaction. On October 25, 2010, the Court entered a Final Order approving this financing transaction. Biovest intends to use the proceeds from the DIP N...",
"Monthly Operating Report of Biovest International, Inc. for the period September 1, 2010 through September 30, 2010 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17796-KRM Document No. 56" |
|
| 09/24/2010 |
8-K
| Form 8-K - Current report |
| 08/20/2010 |
8-K
| Form 8-K - Current report |
| 07/26/2010 |
8-K
| Filed a monthly operating report|
Docs:
|
"FDA Grants Orphan Drug Status for Personalized Cancer Vaccine, BiovaxID®, Targeting Mantle Cell Lymphoma TAMPA, FL and MINNEAPOLIS, MN - July 26, 2010 - Biovest International, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BiovaxID®, Biovest's personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. Mantle cell lymphoma is an aggressive and lethal B-cell blood cancer for which there is no current consensus standard-of-care. Mantle cell lymphoma is the newest disease for which Biovest has announced its intent to pursue regulatory approval for and Orphan Drug Designation represents a significant development step in the Company's regulatory strategy. The FDA previously granted Orphan Drug Designation f...",
"Biovest's Stock Listing Upgraded to OTCQB™ Market TAMPA, FL and MINNEAPOLIS, MN - July 12, 2010 - Biovest International, Inc. , a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports and its Quarterly Reports with the Securities and Exchange Commission , as the Company advances plans to emerge from reorganization. Launched in April 2010, the OTCQB is a new market tier for OTC-traded U.S. companies that are registered and reporting with the SEC. Signaling its plans to emerge from Chapter 11 as a fully reorganized public company, Biovest also announced...",
"Monthly Operating Report of Biovest International, Inc. for the period June 1, 2010 through June 30, 2010 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17796-KRM Document No. 53" |
|
| 06/25/2010 |
8-K
| Filed a monthly operating report |
| 05/26/2010 |
8-K
| Form 8-K - Current report |
| 04/26/2010 |
8-K
| Filed a monthly operating report |
| 03/23/2010 |
8-K
| Form 8-K - Current report |
| 02/22/2010 |
8-K
| Form 8-K - Current report |
| 01/20/2010 |
8-K
| Filed a monthly operating report |
| 12/22/2009 |
8-K
| Filed a monthly operating report |
| 12/01/2009 |
8-K
| Form 8-K - Current report |
| 10/23/2009 |
8-K
| Form 8-K - Current report |
| 08/20/2009 |
8-K
| Form 8-K - Current report |
| 07/20/2009 |
8-K
| Filed a monthly operating report |
| 06/29/2009 |
8-K
| Filed a monthly operating report|
Docs:
|
"Personalized Anti-Cancer Vaccine, BiovaxID®, Targeting B-cell Lymphomas Available in Europe on a Named-Patient Basis - Biovest and idis partner to facilitate patient access to lymphoma vaccine - Phase III study results to be presented at “Best of ASCO” in Paris TAMPA, FLORIDA - June 28, 2009 - Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. today announced that BiovaxID®, Biovest's personalized therapeutic anti-cancer vaccine, is available on a named-patient basis in Europe. Following compliance with local regulatory protocols, BiovaxID will be supplied by idis Limited to European healthcare professionals for the treatment of follicular non-Hodgkin's lymphoma and potentially for other B-cell blood cancers such as chronic lymphocytic le...",
"Monthly Operating Report of Biovest International, Inc. for the period May 1, 2009 through May 31, 2009 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17796-KRM Document No. 32" |
|
| 04/20/2009 |
8-K
| Form 8-K -- Current report |
| 03/20/2009 |
8-K
| Form 8-K -- Current report |
| 02/20/2009 |
8-K
| Form 8-K -- Current report |
| 01/23/2009 |
8-K
| Form 8-K -- Current report |
| 12/24/2008 |
8-K
| Form 8-K -- Current report |
|
|